Drug profile

The FDA adverse-event record for Sam-E

51 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Sam-E. Species, reactions, and outcomes follow.

#1112 of 2,679
by report volume (all drugs)
51
adverse-event reports
7.8%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Sam-E ranks #1098 of 2679 by total reports (51) and #651 of 1130 by death-coded share (7.8%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1098
This drug, reports of 2679
#651
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Sam-E has 51 reports now versus 51 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Sam-E changes

Signature read: death-coded share at 7.8% is the most distinctive stamp on Sam-E's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
51
Total Reports
4
Deaths Reported
7.8%
Death-coded share of reports

Active Ingredients

Sam-E

Administration Routes

OralUnknown

Species Affected

Dog 49
Cat 2

Most Affected Breeds

Retriever - Labrador 6
Crossbred Canine/dog 6
Chihuahua 3
American Pit Bull Terrier 3
Bichon Frise 2
Schnauzer - Miniature 2
Terrier - Boston 2
Maltese 2
Dachshund - Standard Smooth-haired 2
Spaniel (unspecified) 2

Most Reported Reactions

Decreased appetite 10
Lethargy (see also Central nervous system depression in 'Neurological') 10
Elevated alanine aminotransferase (ALT) 10
Elevated serum alkaline phosphatase (SAP) 9
Diarrhoea 8
Underdose 8
Anorexia 7
Panting 5
Vomiting 5
Hyperkalaemia 5
Death by euthanasia 4
Hypoadrenocorticism 4

Outcome Breakdown

Outcome Unknown
30 (58.8%)
Ongoing
11 (21.6%)
Recovered/Normal
6 (11.8%)
Euthanized
4 (7.8%)

Sam-E Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Nationwide drugs with similar profiles

Two openFDA-derived peer sets for Sam-E, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

Similar death-coded share

Nearest other drugs by death-coded share (7.8% here), distinct from the volume row.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Sam-E (#1112 of 2,679 by report volume); death-coded 7.8%. PlainBreed drug row · death-coded share stamp 7.8% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →